Neurotoxicity of valacyclovir in peritoneal dialysis: A pharmacokinetic study

American Journal of Nephrology

Volumn 21, Issue 2, 2001, Pages 162-164

  Izzedine, Hassane ^a   Mercadal, Lucile ^a   Aymard, Guy ^a   Launay Vacher, Vincent ^a   Martinez, Valérie ^a   Issad, Belkassem ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Peritoneal dialysis; Valacyclovir, neurotoxicity; Valacyclovir, pharmacokinetics

Indexed keywords

ANTIVIRUS AGENT; VALACICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; FEMALE; HERPES ZOSTER; HUMAN; KIDNEY FAILURE; NEUROTOXICITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION;

ACYCLOVIR; ANTIVIRAL AGENTS; FEMALE; HALLUCINATIONS; HERPES ZOSTER; HUMANS; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PRODRUGS; VALINE;

EID: 0035000354     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046241     Document Type: Article

References (11)

1. Perry CM, Faulds D: Valacyclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections. Drugs 1996;52:754-772.
2. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
3. Soul-Lawton J, Seaber E, Oh N, et al: Absolute bioavailability and metabolic disposition of valacyclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39:2759-2764.
4. Weller S, Blum MR, Doucette M, et al: Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
5. Revankar SG, Applegate AL, Markovitz DM: Delirium associated with acyclovir treatment in a patient with renal failure. Clin Infect Dis 1995;21:435-436.
6. Laskin OL, Longstreth JA, Whelton A, et al: Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 1982;73:197-201.
7. Linssen-Schuurmans C, Van Kan EJM, Feith GW, Uges DRA: Neurotoxicity caused by valacyclovir in a patient on hemodialysis. Ther Drug Monit 1998;20:385-386.
8. Wang LH, Schultz M, Weller S: Pharmacokinetics and safety of multiple-dose valacyclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob Agents Chemother 1996;40:80-85.
9. Haefali WE, Schoenenberger R, Weiss P, Ritz R: Acyclovir-induced neurotoxicity: Concentration-side effect relationship in acyclovir overdosage. Am J Med 1993;94:212-215.
10. Wagstaff AJ, Faulds D, Goa KL: Acyclovir: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
11. Stathoupoulou F, Almond MK, Dhillon S, Raftery MJ: Clinical pharmacokinetics of oral acyclovir in patients in continuous ambulatory peritoneal dialysis. Nephron 1996;74:337-341.